Actively Recruiting
The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
Led by University of Alabama at Birmingham · Updated on 2026-04-30
205
Participants Needed
1
Research Sites
532 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary objective of this substudy is to measure the concentration and the regional brain distribution of activated brain microglia/macrophages using the PET ligand \[18F\]DPA-714 in participants enrolled in the UAB Innate and Adaptive Immunity in Parkinson's Disease (Clinical Research Core) and Longitudinal \[18F\]DPA-714 Imaging in a Parkinson Disease Cohort studies. The PET tracer \[18F\]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated microglia/macrophages and provides a non-invasive measure of neuroinflammation. The amount and distribution of \[18F\]DPA-714 in the brain will be correlated to clinical data acquired through the separate ongoing UAB Innate and Adaptive Immunity in Parkinson Disease (Clinical Research Core) and Longitudinal \[18F\]DPA-714 Imaging in a Parkinson Disease Cohort studies. The primary objective of this study is to determine if patients with PD have higher levels of neuroinflammation than healthy controls as measured with \[18F\]DPA-714-PET/MRI.
CONDITIONS
Official Title
The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Enrollment in either the UAB Innate and Adaptive Immunity in Parkinson Disease (Clinical Research Core) study or the UAB Longitudinal [18F]DPA-714 Imaging in a Parkinson Disease Cohort study
- Negative pregnancy test within 2 days before PET scan for women who can become pregnant; women who are post-menopausal for at least 1 year or surgically sterile do not require testing
- High or mixed affinity binding to TSPO ligands based on genetic testing
- For the UDALL 5-year Follow-up Cohort: Parkinson's Disease participant enrolled in UDALL Baseline Cohort with baseline imaging completed within the last 6 years
- Participants must be 30 years of age or older
You will not qualify if you...
- Any exclusion criteria from the UAB Innate and Adaptive Immunity in Parkinson Disease (Clinical Research Core) or UAB Longitudinal [18F]DPA-714 Imaging in Parkinson Disease Cohort studies
- Contraindications to MRI or PET imaging
- Unable to participate in imaging studies due to severity of Parkinson's Disease or other medical conditions
- Low affinity binding to TSPO ligands based on genetic testing
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UAB Advanced Imaging Facility
Birmingham, Alabama, United States, 35294
Actively Recruiting
Research Team
J
Jonathan McConathy, MD
CONTACT
E
Evan Hudson
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here